-+ 0.00%
-+ 0.00%
-+ 0.00%

Capricorn Therapeutics shares rose 65% after the US Food and Drug Administration agreed to review the latest data on its new Duchenne muscular dystrophy drug.

Zhitongcaijing·08/14/2026 13:33:15
Listen to the news
Capricorn Therapeutics shares rose 65% after the US Food and Drug Administration agreed to review the latest data on its new Duchenne muscular dystrophy drug.